Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 1 to 25 of 379

Sort by

Type: GuidanceRemove Type: Guidance filter
Type: Quality standardRemove Type: Quality standard filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]	Technology appraisal guidance	TBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]	Technology appraisal guidance	TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533	Technology appraisal guidance	TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]	Technology appraisal guidance	TBC
Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media	NICE guideline	16 October 2024
Adrenal insufficiency: identification and management	NICE guideline	28 August 2024
Alcohol-mediated perivascular renal denervation for resistant hypertension	Interventional procedures guidance	5 February 2025
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]	Technology appraisal guidance	11 December 2024
ALXN1840 for treating Wilson disease TS ID 9950	Technology appraisal guidance	TBC
Alzheimer's disease (early) - gantenerumab [ID6142]	Technology appraisal guidance	TBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]	Technology appraisal guidance	TBC
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]	Technology appraisal guidance	18 December 2024
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]	Technology appraisal guidance	TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance	TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]	Highly specialised technology	TBC
Artificial intelligence software to help detect fractures in the emergency department (provisional title)	Health technology evaluation	17 December 2024
Artificial Intelligence technologies for assessing skin lesions selected for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments	Diagnostics guidance	TBC
Asthma: diagnosis, monitoring and chronic asthma management	NICE guideline	30 October 2024
Asunercept for treating glioblastoma [1301]	Technology appraisal guidance	TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable ID6218	Technology appraisal guidance	TBC

Results per page

10
25
50
All